Usefulness of markers of cell proliferation in the management of pituitary adenomas

Marco Losa, Alberto Franzin, Pietro Mortini, Maria Rosa Terreni, Francesca Mangili, Massimo Giovanelli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

1. Pituitary adenomas are benign and slow-growing tumours whose clinical manifestations depend mainly on the secretory activity of the adenomatous cells. Except for prolactinomas, surgical removal of the tumour is the therapy of choice. 2. Despite extensive research on their clinical and pathophysiological aspects, few studies have explored the oncological characteristics of these rare lesions. Among these, the growth fraction of pituitary adenomas has been determined by different methods, of which the most useful are those performed in archival material. 3. The results reported in the literature show that adrenocorticotropic hormone-secreting tumours seem to be characterized by a higher proliferation index than the other types of pituitary adenomas, despite their usually small tumour size. 4. In small series of patients radiotherapy and medical treatment with dopaminergic drugs and octreotide were associated with a lower proliferation index than untreated tumours. Tumour size was not correlated with the growth fraction of the pituitary tumours, whereas invasiveness was correlated in most studies. 5. From a clinical point of view, however, the more promising utilization of the proliferation index seems to be in predicting the potential of recurrence of the tumour, thus allowing a more rational approach to follow-up and further treatment of patients with pituitary adenomas.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalClinical Science
Volume95
Issue number2
Publication statusPublished - 1998

Fingerprint

Pituitary Neoplasms
Cell Proliferation
Neoplasms
Prolactinoma
Dopamine Agents
Octreotide
Growth
Adrenocorticotropic Hormone
Radiotherapy
Therapeutics
Recurrence
Research

Keywords

  • Cell proliferation
  • Growth fraction
  • Pituitary neoplasm
  • Pituitary surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Losa, M., Franzin, A., Mortini, P., Terreni, M. R., Mangili, F., & Giovanelli, M. (1998). Usefulness of markers of cell proliferation in the management of pituitary adenomas. Clinical Science, 95(2), 129-135.

Usefulness of markers of cell proliferation in the management of pituitary adenomas. / Losa, Marco; Franzin, Alberto; Mortini, Pietro; Terreni, Maria Rosa; Mangili, Francesca; Giovanelli, Massimo.

In: Clinical Science, Vol. 95, No. 2, 1998, p. 129-135.

Research output: Contribution to journalArticle

Losa, M, Franzin, A, Mortini, P, Terreni, MR, Mangili, F & Giovanelli, M 1998, 'Usefulness of markers of cell proliferation in the management of pituitary adenomas', Clinical Science, vol. 95, no. 2, pp. 129-135.
Losa, Marco ; Franzin, Alberto ; Mortini, Pietro ; Terreni, Maria Rosa ; Mangili, Francesca ; Giovanelli, Massimo. / Usefulness of markers of cell proliferation in the management of pituitary adenomas. In: Clinical Science. 1998 ; Vol. 95, No. 2. pp. 129-135.
@article{28fdd02d14b24ac6ba97ee3c5b8b015d,
title = "Usefulness of markers of cell proliferation in the management of pituitary adenomas",
abstract = "1. Pituitary adenomas are benign and slow-growing tumours whose clinical manifestations depend mainly on the secretory activity of the adenomatous cells. Except for prolactinomas, surgical removal of the tumour is the therapy of choice. 2. Despite extensive research on their clinical and pathophysiological aspects, few studies have explored the oncological characteristics of these rare lesions. Among these, the growth fraction of pituitary adenomas has been determined by different methods, of which the most useful are those performed in archival material. 3. The results reported in the literature show that adrenocorticotropic hormone-secreting tumours seem to be characterized by a higher proliferation index than the other types of pituitary adenomas, despite their usually small tumour size. 4. In small series of patients radiotherapy and medical treatment with dopaminergic drugs and octreotide were associated with a lower proliferation index than untreated tumours. Tumour size was not correlated with the growth fraction of the pituitary tumours, whereas invasiveness was correlated in most studies. 5. From a clinical point of view, however, the more promising utilization of the proliferation index seems to be in predicting the potential of recurrence of the tumour, thus allowing a more rational approach to follow-up and further treatment of patients with pituitary adenomas.",
keywords = "Cell proliferation, Growth fraction, Pituitary neoplasm, Pituitary surgery",
author = "Marco Losa and Alberto Franzin and Pietro Mortini and Terreni, {Maria Rosa} and Francesca Mangili and Massimo Giovanelli",
year = "1998",
language = "English",
volume = "95",
pages = "129--135",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Usefulness of markers of cell proliferation in the management of pituitary adenomas

AU - Losa, Marco

AU - Franzin, Alberto

AU - Mortini, Pietro

AU - Terreni, Maria Rosa

AU - Mangili, Francesca

AU - Giovanelli, Massimo

PY - 1998

Y1 - 1998

N2 - 1. Pituitary adenomas are benign and slow-growing tumours whose clinical manifestations depend mainly on the secretory activity of the adenomatous cells. Except for prolactinomas, surgical removal of the tumour is the therapy of choice. 2. Despite extensive research on their clinical and pathophysiological aspects, few studies have explored the oncological characteristics of these rare lesions. Among these, the growth fraction of pituitary adenomas has been determined by different methods, of which the most useful are those performed in archival material. 3. The results reported in the literature show that adrenocorticotropic hormone-secreting tumours seem to be characterized by a higher proliferation index than the other types of pituitary adenomas, despite their usually small tumour size. 4. In small series of patients radiotherapy and medical treatment with dopaminergic drugs and octreotide were associated with a lower proliferation index than untreated tumours. Tumour size was not correlated with the growth fraction of the pituitary tumours, whereas invasiveness was correlated in most studies. 5. From a clinical point of view, however, the more promising utilization of the proliferation index seems to be in predicting the potential of recurrence of the tumour, thus allowing a more rational approach to follow-up and further treatment of patients with pituitary adenomas.

AB - 1. Pituitary adenomas are benign and slow-growing tumours whose clinical manifestations depend mainly on the secretory activity of the adenomatous cells. Except for prolactinomas, surgical removal of the tumour is the therapy of choice. 2. Despite extensive research on their clinical and pathophysiological aspects, few studies have explored the oncological characteristics of these rare lesions. Among these, the growth fraction of pituitary adenomas has been determined by different methods, of which the most useful are those performed in archival material. 3. The results reported in the literature show that adrenocorticotropic hormone-secreting tumours seem to be characterized by a higher proliferation index than the other types of pituitary adenomas, despite their usually small tumour size. 4. In small series of patients radiotherapy and medical treatment with dopaminergic drugs and octreotide were associated with a lower proliferation index than untreated tumours. Tumour size was not correlated with the growth fraction of the pituitary tumours, whereas invasiveness was correlated in most studies. 5. From a clinical point of view, however, the more promising utilization of the proliferation index seems to be in predicting the potential of recurrence of the tumour, thus allowing a more rational approach to follow-up and further treatment of patients with pituitary adenomas.

KW - Cell proliferation

KW - Growth fraction

KW - Pituitary neoplasm

KW - Pituitary surgery

UR - http://www.scopus.com/inward/record.url?scp=0031667537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031667537&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 129

EP - 135

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 2

ER -